News
Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results